Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Blood (2024) 144 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2024-199287

Published: 2024

Journal Articles

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Blood (2024) 144 (4): 392–401.

https://doi.org/10.1182/blood.2024023847

Published: 2024

Includes: Supplemental data

Journal Articles

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy

Sara Ghorashian, FRCPath, PhD, Sujith Samarasinghe, Amy A Kirkwood, MSc, Rachael Hough, MD BMBS, FRCP, FRCPath, Clare Rowntree, MD, Sarah Lawson, MD, Nicholas John Goulden, MD PhD MRCPath, Emma Pond, PhD, Pamela R. Kearns, PhDFRCPC, Anthony V. Moorman, PhD, John Moppett, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 656.

https://doi.org/10.1182/blood-2018-99-118426

Published: 2018

Journal Articles

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Blood (2018) 132 (Supplement 1): 572.

https://doi.org/10.1182/blood-2018-99-111901

Published: 2018

Journal Articles

UKALL 2011: Randomised Trial Investigating a Short Induction Dexamethasone Schedule for Children and Young Adults with Acute Lymphoblastic Leukaemia

Nicholas John Goulden, MD PhD MRCPath, Amy A Kirkwood, John Moppett, MD, Sujith Samarasinghe, Sarah Lawson, MD, Clare Rowntree, MD, Rachael Hough, MD BMBS, FRCP, FRCPath, Rajbir Athwal, Pamela R. Kearns, PhDFRCPC, Ajay Vora, MD

Blood (2017) 130 (Supplement 1): 141.

https://doi.org/10.1182/blood.V130.Suppl_1.141.141

Published: 2017

Journal Articles

Dexamethasone Pharmacokinetics Following Standard and Short Dosing Schedules in Patients on the UKALL2011 Trial

Rosanna Jackson, BSc, MSc, Philip Berry, BSc, Julie Errington, MSc, John Moppett, MD, Sujith Samarasinghe, Rachael Hough, MD BMBS, FRCP, FRCPath, Clare Rowntree, MD, Nicholas John Goulden, MD PhD MRCPath, Ajay Vora, MD, Pamela R. Kearns, PhDFRCPC, Julie Irving, PhD, Gareth J Veal, PhD

Blood (2017) 130 (Supplement 1): 101.

https://doi.org/10.1182/blood.V130.Suppl_1.101.101

Published: 2017

Journal Articles

Management of adults with T-cell lymphoblastic leukemia

David I. Marks, Clare Rowntree

Blood (2017) 129 (9): 1134–1142.

https://doi.org/10.1182/blood-2016-07-692608

Published: 2017

Journal Articles

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Dina Okasha, Amy A Kirkwood, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Emma Lawrie, Andrew McMillan, PhD, Tobias F. Menne, MD PhD FRCPath, Nick Morley, Clare Rowntree, Deborah Susan Richardson, MDFRCPath,FRCP,MA,MBBChir, Paul Smith, Adele K. Fielding, MB BS, PhD, David Marks, MD PhD

Blood (2015) 126 (23): 733.

https://doi.org/10.1182/blood.V126.23.733.733

Published: 2015

Journal Articles

Use of Morphological Early Response Data to Predict Relapse in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)

Caroline L Furness, MD, Clare Rowntree, Ajay J. Vora, Amy A Kirkwood, Christopher Mitchell, MBBS, PhD FRCP, Nicholas Goulden, MD PhD, Anthony V. Moorman, PhD, Rachael Hough, MDBMBS,FRCP,FRCPath

Blood (2015) 126 (23): 1415.

https://doi.org/10.1182/blood.V126.23.1415.1415

Published: 2015

Journal Articles

Analysis of Long-Term Outcomes, Management and Prevalence of Osteonecrosis in UKALL 2003: 3.5% of Adolescents and Young Adults over 10 Years of Age with Acute Lymphoblastic Leukaemia Required Hip Replacement

Nadia L Amin, MBChB, MSc, MA, Sally Kinsey, MD FRCP, FRCPath, Richard Feltbower, PhD MSc, BSc, Ajay J. Vora, Nicholas Goulden, MD PhD, Rachel Wade, MSc, Chris Mitchell, FRCPCH, Rachael Hough, MDBMBS,FRCP,FRCPath, Clare Rowntree, PhD, Beki James, PhD MBChB, MA

Blood (2015) 126 (23): 2083.

https://doi.org/10.1182/blood.V126.23.2083.2083

Published: 2015

Journal Articles

Relapse in Teenage and Young Adult (TYA) Patients Treated on a Pediatric Minimal Residual Disease (MRD) Stratified Protocol Is Associated with a Poor Outcome: Results from UKALL2003

Rob S Sellar, MBChB, FRCPath, Clare Rowntree, PhD, Ajay J. Vora, Caroline L Furness, MD, Nicholas Goulden, MD PhD, Chris Mitchell, FRCPCH, Anthony V. Moorman, PhD, Rachael Hough, MDBMBS,FRCP,FRCPath

Blood (2015) 126 (23): 2493.

https://doi.org/10.1182/blood.V126.23.2493.2493

Published: 2015

Journal Articles

Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial

Katharine Patrick, Rachel Wade, Nicholas Goulden, MD PhD, Chris Mitchell, Clare Rowntree, FRCPath, Jeremy Hancock, Rachael E Hough, MD, Ajay J. Vora, FRCPath

Blood (2014) 124 (21): 3702.

https://doi.org/10.1182/blood.V124.21.3702.3702

Published: 2014

Journal Articles

Characteristics and Outcome Of Children and Young Adults With Early T-Precusor (ETP) ALL Treated On UKALL 2003

Katharine Patrick, FRCPath, Rachel Wade, Nicholas Goulden, Chris Mitchell, PhD, Clare Rowntree, FRCPath, Rachael E Hough, MD, Ajay J Vora

Blood (2013) 122 (21): 58.

https://doi.org/10.1182/blood.V122.21.58.58

Published: 2013

Journal Articles

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

Nahid Zareian, Bella Patel, MBBS, FRCPath, Lena Rai-Shetty, PhD, Clare Rowntree, PhD, Andrew McMillan, FRCP, FRCPath, PhD, David I Marks, Tobias Menne, Paul Smith, Simon Purnell, Lynda Micklewright, Anthony V. Moorman, Adele Fielding, MB BS, PhD

Blood (2013) 122 (21): 1335.

https://doi.org/10.1182/blood.V122.21.1335.1335

Published: 2013

Journal Articles

Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria

Lorna Anne Fern, BSc, MSc, PhD, Clare Rowntree, PhD, Rachael E Hough, MD, Ajay J Vora, Adele Fielding, MB BS, PhD, Chris Mitchell, Nicholas Goulden, Robert Alston, PhD, Jillian Birch, MD, O'hara Catherine, PhD, Jeremy Whelan, MD FRCP

Blood (2013) 122 (21): 1401.

https://doi.org/10.1182/blood.V122.21.1401.1401

Published: 2013

Journal Articles

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Bella Patel, MB, BS, MD, A Kirkwood, Aditi Dey, Clare Rowntree, Andrew McMillan, FRCP, FRCPath, PhD, David Marks, MD, PhD, Tobias Menne, Paul Smith, PhD, Simon Purnell, Lynda Micklewright, Adele K Fielding, MB, BS, PhD

Blood (2013) 122 (21): 3900.

https://doi.org/10.1182/blood.V122.21.3900.3900

Published: 2013

Journal Articles

Outcomes Of Teenagers and Young Adults On The UKALL 2003 Paediatric Trial For Children and Young People With Acute Lymphoblastic Leukaemia

Clare Rowntree, PhD, Rachael E Hough, MD, Rachel Wade, Nicholas Goulden, Chris Mitchell, PhD, Ajay J Vora

Blood (2013) 122 (21): 57.

https://doi.org/10.1182/blood.V122.21.57.57

Published: 2013

Journal Articles

Characteristics and Outcomes Of Patients With Down Syndrome Associated Acute Lymphoblastic Leukaemia Treated On UKALL 2003

Katharine Patrick, FRCPath, Rachel Wade, MSc, Nicholas Goulden, Clare Rowntree, FRCPath, Rachael Hough, FRCPath, Christopher D Mitchell, FRCPCH, Ajay J Vora

Blood (2013) 122 (21): 56.

https://doi.org/10.1182/blood.V122.21.56.56

Published: 2013

Journal Articles

Impact Of Age On Toxicity Associated With Chemotherapy For Acute Lymphoblastic Leukaemia (ALL): Results From The UK Prospective Study UKALL2003

Rachael E. Hough, MD, Clare Rowntree, Rachel Wade, Nicholas Goulden, Chris Mitchell, Ajay J. Vora

Blood (2013) 122 (21): 840.

https://doi.org/10.1182/blood.V122.21.840.840

Published: 2013

Journal Articles

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema

Ajay J Vora, FRCPath, Nicholas Goulden, FRCPath, Christopher D Mitchell, FRCPCH, Rachael Hough, FRCPath, Clare Rowntree, FRCPath, Susan M Richards, Ph.D

Blood (2012) 120 (21): 136.

https://doi.org/10.1182/blood.V120.21.136.136

Published: 2012

NARROW

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

UKALL 2011: Randomised Trial Investigating a Short Induction Dexamethasone Schedule for Children and Young Adults with Acute Lymphoblastic Leukaemia

Dexamethasone Pharmacokinetics Following Standard and Short Dosing Schedules in Patients on the UKALL2011 Trial

Management of adults with T-cell lymphoblastic leukemia

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Use of Morphological Early Response Data to Predict Relapse in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)

Analysis of Long-Term Outcomes, Management and Prevalence of Osteonecrosis in UKALL 2003: 3.5% of Adolescents and Young Adults over 10 Years of Age with Acute Lymphoblastic Leukaemia Required Hip Replacement

Relapse in Teenage and Young Adult (TYA) Patients Treated on a Pediatric Minimal Residual Disease (MRD) Stratified Protocol Is Associated with a Poor Outcome: Results from UKALL2003

Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial

Characteristics and Outcome Of Children and Young Adults With Early T-Precusor (ETP) ALL Treated On UKALL 2003

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Outcomes Of Teenagers and Young Adults On The UKALL 2003 Paediatric Trial For Children and Young People With Acute Lymphoblastic Leukaemia

Characteristics and Outcomes Of Patients With Down Syndrome Associated Acute Lymphoblastic Leukaemia Treated On UKALL 2003

Impact Of Age On Toxicity Associated With Chemotherapy For Acute Lymphoblastic Leukaemia (ALL): Results From The UK Prospective Study UKALL2003

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only